Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 01 Oct 2021
TG Therapeutics submits biologics license application to the U.S. FDA for ublituximab as a treatment for patients with relapsing forms of multiple sclerosis
30 September 2021 - TG Therapeutics today announced the submission of a biologics license application to the U.S. FDA requesting approval ...
Posted by Michael Wonder on 01 Oct 2021
Xbrane Biopharma announces that partner Stada's marketing authorisation application for ranibizumab is submitted and validated by European Medicines Agency
30 September 2021 - Xbrane Biopharma today announces that a marketing authorisation Application for biosimilar ranibizumab submitted by its co-development ...
Posted by Michael Wonder on 30 Sep 2021
NICE terminates another two appraisals
29 September 2021 - Four terminations for the month. ...
Posted by Michael Wonder on 30 Sep 2021
U.S. House panel approves fourth bill aimed at drug prices
30 September 2021 - The U.S. House Judiciary Committee voted Thursday to approve a fourth bill aimed at tackling high ...
Posted by Michael Wonder on 30 Sep 2021
DiaMedica Therapeutics announces fast track designation granted to DM199 for the treatment of acute ischaemic stroke
30 September 2021 - DiaMedica Therapeutics today announced that the U.S. FDA has granted fast track designation to the Company’s lead ...
Posted by Michael Wonder on 30 Sep 2021
Schedule of Pharmaceutical Benefits - 1 October 2021
1 October 2021 - The October 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Sep 2021
FDA grants priority review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer
28 September 2021 - Novartis announced today that the US FDA has accepted and granted Priority Review to the company’s New ...
Posted by Michael Wonder on 30 Sep 2021
FDA clears first major imaging device advancement for computed tomography in nearly a decade
30 September 2021 - The device uses the emerging CT technology of photon counting detectors which can measure each individual X-ray ...
Posted by Michael Wonder on 30 Sep 2021
TLV gets a leading role in European HTA project
29 September 2021 - TLV is one of 13 European authorities that are now part of a project called EUnetHTA21. ...
Posted by Michael Wonder on 30 Sep 2021
People with advanced or metastatic urothelial cancer to get life-extending treatment
30 September 2021 - Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will be eligible for ...
Posted by Michael Wonder on 30 Sep 2021
New Zealand Pharmaceutical Schedule - 1 October 2021
1 October 2021 - The October 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Sep 2021
COVID-19 vaccine weekly safety report (30 September 2021)
30 September 2021 - To 26 September 2021, approximately 26.8 million vaccine doses have been given in Australia – 16.1 million ...
Posted by Michael Wonder on 30 Sep 2021
Medicines industry continues to protect Australians from medicine shortages
30 September 2021 - ACCC extends approval for ongoing collaboration ...
Posted by Michael Wonder on 30 Sep 2021
Acacia Pharma announces submission and validation of marketing authorisation application for Barhemsys (amisulpride injection) in major European markets
29 September 2021 - Acacia Pharma announces that its marketing authorisation application for Barhemsys (amisulpride injection) has been submitted, validated and ...
Posted by Michael Wonder on 30 Sep 2021
Kesimpta: game changing multiple sclerosis drug now on PBS
30 September 2021 - A new drug that promises to change the lives of thousands of Australians living with multiple sclerosis ...